Blueprint Medicines is a patient-driven oncology company developing highly selective kinase inhibitors for genomically defined cancer subsets. Led by a management team and advisors with world-renowned expertise in cancer genomics, drug discovery and clinical oncology, Blueprint has developed a platform that combines genomics with a novel library of kinase inhibitors, enabling Blueprint to rapidly develop potent highly selective compounds against clear genomic driver targets.
September 17, 2013
Blueprint Medicines Appoints Oncology Business Leader Kyle Kuvalanka as Chief Business … [Read More...]
March 19, 2013
Blueprint Medicines Announces First Collaboration with Wellcome Trust Sanger Institute And … [Read More...]